What do systematic reviews say?

Pegylated interferon + ribavirin (24 weeks) + initial telepravir (12 weeks) vs pegylated interferon (48 weeks) + initial telepravir (12 weeks) + initial low dose ribavirin (12 + 36 weeks)

It is very uncertain whether pegylated interferon + ribavirin (24 weeks) + initial telepravir (12… changes sustained virological response compared with pegylated interferon (48 weeks) + initial telepravir (12 weeks) +… (very low certainty).

• Interventions for dialysis patients with hepatitis C virus (HCV) infection 2023 · Cochrane Headline outcomes only
  RR 1.02 [0.67, 1.56]
  1 study · 35 participants
  Very low

Pegylated interferon + ribavirin (24 weeks) + initial telepravir (12 weeks) vs pegylated interferon (48 weeks) + initial telepravir (12 weeks) + initial low dose ribavirin (12 + 36 weeks)

It is very uncertain whether pegylated interferon + ribavirin (24 weeks) + initial telepravir (12… changes end‐of‐treatment response compared with pegylated interferon (48 weeks) + initial telepravir (12 weeks) +… (very low certainty).

• Interventions for dialysis patients with hepatitis C virus (HCV) infection 2023 · Cochrane Headline outcomes only
  RR 1.02 [0.67, 1.56]
  1 study · 35 participants
  Very low

Pegylated interferon + ribavirin (24 weeks) + initial telepravir (12 weeks) vs pegylated interferon (48 weeks) + initial telepravir (12 weeks) + initial low dose ribavirin (12 + 36 weeks)

The review found no eligible studies for this question.

• Interventions for dialysis patients with hepatitis C virus (HCV) infection 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Standard interferon vs placebo or control

Standard interferon showed no clear difference in treatment discontinuation compared with placebo or control (moderate certainty).

• Interventions for dialysis patients with hepatitis C virus (HCV) infection 2023 · Cochrane Headline outcomes only
  RR 4.59 [0.49, 42.69]
  4 studies · 116 participants
  Moderate

Pegylated interferon + ribavirin (24 weeks) + initial telepravir (12 weeks) vs pegylated interferon (48 weeks) + initial telepravir (12 weeks) + initial low dose ribavirin (12 + 36 weeks)

The review found no eligible studies for this question.

• Interventions for dialysis patients with hepatitis C virus (HCV) infection 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Standard interferon vs placebo or control

Standard interferon showed no clear difference in adverse events compared with placebo or control (moderate certainty).

• Interventions for dialysis patients with hepatitis C virus (HCV) infection 2023 · Cochrane Headline outcomes only
  RR 3.56 [0.98, 13.01]
  5 studies · 143 participants
  Moderate

Pegylated (PEG) interferon alpha‐2a vs standard interferon

Pegylated interferon alpha‐2a showed no clear difference in death compared with standard interferon (low certainty).

• Interventions for dialysis patients with hepatitis C virus (HCV) infection 2023 · Cochrane Headline outcomes only
  RR 0.33 [0.01, 7.81]
  1 study · 50 participants
  Low

Pegylated (PEG) interferon alpha‐2a vs standard interferon

Pegylated interferon alpha‐2a showed no clear difference in relapse(recurrence after stopping) compared with standard interferon (low certainty).

• Interventions for dialysis patients with hepatitis C virus (HCV) infection 2023 · Cochrane Headline outcomes only
  RR 0.72 [0.41, 1.25]
  1 study · 38 participants
  Low

Pegylated (PEG) interferon alpha‐2a vs standard interferon

Pegylated interferon alpha‐2a may leads to higher end‐of‐treatment response compared with standard interferon (low certainty).

• Interventions for dialysis patients with hepatitis C virus (HCV) infection 2023 · Cochrane Headline outcomes only
  RR 1.53 [1.09, 2.15]
  1 study · 50 participants
  Low

Exercise vs control

• Interventions for fatigue in people with kidney failure requiring dialysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 217 participants
  Low

Aromatherapy vs placebo or usual care

The review found no eligible studies for this question.

• Interventions for fatigue in people with kidney failure requiring dialysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Aromatherapy vs placebo or usual care

The review found no eligible studies for this question.

• Interventions for fatigue in people with kidney failure requiring dialysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Aromatherapy vs placebo or usual care

The review found no eligible studies for this question.

• Interventions for fatigue in people with kidney failure requiring dialysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Acupressure vs placebo or control

• Interventions for fatigue in people with kidney failure requiring dialysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  6 studies · 459 participants
  Low

Exercise vs control

The review found no eligible studies for this question.

• Interventions for fatigue in people with kidney failure requiring dialysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Acupressure vs placebo or control

The review found no eligible studies for this question.

• Interventions for fatigue in people with kidney failure requiring dialysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Acupressure vs placebo or control

The review found no eligible studies for this question.

• Interventions for fatigue in people with kidney failure requiring dialysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Acupressure vs placebo or control

The review found no eligible studies for this question.

• Interventions for fatigue in people with kidney failure requiring dialysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Acupressure vs placebo or control

The review found no eligible studies for this question.

• Interventions for fatigue in people with kidney failure requiring dialysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Acupressure vs placebo or control

The review found no eligible studies for this question.

• Interventions for fatigue in people with kidney failure requiring dialysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found